DD vs URGN · P/E 127, rev $3.50B vs rev $123.4M
Dupont De Nemours Inc (DD) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Dupont De Nemours Inc (DD) is a specialty chemicals company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported DD revenue for 2026-06-30 was $3.50B. Net income was $304.0M. DD currently screens at market cap $19.61B and trailing P/E 127.4.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
DD currently screens at market cap $19.61B and trailing P/E 127.4. URGN currently screens at market cap $1.61B.
Not investment advice. Open the DD and URGN stock pages for the full models.
Not investment advice.